Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

Merck KGaA :, Darmstadt, Germany, Licenses Four Oncology Research and Development Programs from Vertex and Becomes a Leader in DNA Damage and Repair

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/19/2017 | 07:38pm CET

By a News Reporter-Staff News Editor at Drug Week -- Merck KGaA, Darmstadt, Germany, a leading science and technology company which operates its biopharmaceutical business in the US and Canada as EMD Serono, announced that it has entered into a licensing agreement with Vertex Pharmaceuticals Incorporated, Boston, USA, for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer (see also Pharmaceutical Companies).

"With this strategic deal, we significantly strengthen our oncology pipeline in two attractive areas where we have leading competence, DNA damage and repair and immuno-oncology-areas which also have promising therapeutic synergy," says Belen Garijo, CEO Healthcare and Member of the Executive Board of Merck KGaA, Darmstadt, Germany. "This deal underscores our commitment to accelerate innovation for cancer patients, and we are excited for the opportunity to build on Vertex's rigorous science and advance these leading programs."

As part of the agreement, Merck KGaA, Darmstadt, Germany will license two clinical-stage programs targeting DNA damage and repair, along with two additional novel pre-clinical programs. Vertex will receive an upfront payment of $230 million, in addition to royalties on future net sales. Merck KGaA, Darmstadt, Germany will assume full responsibility for the development and commercialization of all the programs.

"The Vertex R&D team has produced a portfolio of first-in-class compounds with the potential to enhance the therapy of multiple cancers," said Jeffrey Leiden, Chairman, President and CEO of Vertex. "We are pleased to partner with Merck KGaA, Darmstadt, Germany, a leader in oncology with exciting complementary assets that will help fully realize the value of these unique compounds and accelerate the programs' potential benefits for patients."

Keywords for this news article include: Pharmaceutical Companies, Genetics, Oncology, DNA Damage, Proteomics, DNA Research, Deoxyribonucleic Acid, Merck KGaA Darmstadt Germany.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
01/19 MERCK KGAA : Darmstadt, Germany, Licenses Four Oncology Research and Development..
01/19 MERCK KGAA : Darmstadt, Germany, and Palantir Launch New Healthcare Acceleration..
01/18 MERCK : Launches First Commercial Screening Service to Predict Multiple Sources ..
01/18 MERCK : MilliporeSigma Kicks Off Year-Long 'Curiosity Cube' Tour
01/18 MERCK : And Palantir Technologies Inc Agree On Cancer Data Analysis Pact
01/17 MERCK : Moves Executives Between Businesses and Group Functions
01/17 MERCK : Opens Production Facility Exclusively for Meglumine in Spain
01/16 MERCK : Drives Business Opportunities in the U.S. to Foster Innovation Across al..
01/13 MERCK : Introduces New Calibration Kit for In Vitro Diagnostic Use
01/12 MERCK : MilliporeSigma Kicks Off Year-Long ‘Curiosity Cube™’ T..
More news
Sector news : Specialty & Advanced Pharmaceuticals
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
01/19 GSK grabs Astra executive to replace pharma head
01/19DJGLAXOSMITHKLINE : Global Pharmaceuticals President Abbas Hussain to Leave -- Upd..
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
01/18 Astra's Mystic Mystery And Other Surprises In Store
01/12 Vertex And German Merck Find Their Perfect Fit
01/12 JPMorgan Day Three Roundup - Trump Reminds The Sector Who's In Charge
01/11 Vertex to collaborate with Germany's Merck in oncology
01/10 German Merck Unveils Its Secret Weapon
Advertisement
Financials (€)
Sales 2016 15 044 M
EBIT 2016 3 509 M
Net income 2016 1 706 M
Debt 2016 11 023 M
Yield 2016 1,19%
P/E ratio 2016 25,92
P/E ratio 2017 22,97
EV / Sales 2016 1,62x
EV / Sales 2017 1,44x
Capitalization 13 351 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108 €
Spread / Average Target 4,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA3.08%14 207
ABBVIE INC-1.53%100 204
KYOWA HAKKO KIRIN CO L..-2.22%7 882
JAZZ PHARMACEUTICALS P..17.96%7 703
MALLINCKRODT PLC-8.75%4 926
ZHANGZHOU PIENTZEHUANG..-1.16%3 988
More Results